Bavarian Nordic secures second part of smallpox vaccine order from the US

The order, which was made public in April 2020, is worth USD 200m.

Photo: Bavarian Nordic / PR

Bavarian Nordic has secured the second part of a smallpox vaccine order from the US government, as Biomedical Advanced Research and Development Authority (BARDA) has exercised an option. Bavarian Nordic announces this on Wednesday evening.

The order, which was made public in April this year, is at USD 200m, out of which the first USD 106m, which covers both the manufacturing of bulk vaccine and the supply of liquid-frozen Jynneos doses, was secured upon contract award in April.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs